Name: Immix Biopharma, Inc. (IMMX) Financial Statements
Creator: FinSpry

Immix Biopharma Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Immix Biopharma, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	0.00	0.00	0.00	0.00	0.00
Cost of Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00
Operating Expenses
Research & Development	11.29	8.74	4.20	0.13	0.25
Selling, General & Administrative	11.38	7.41	4.02	1.23	0.21
Operating Expenses	22.67	16.14	8.22	1.35	0.45
Operating Income	-22.67	-16.14	-8.22	-1.35	-0.45
Other Income/Expense
Interest Income	1.02	0.57	0.00	0.00	0.00
Interest Expense	0.00	0.00	0.00	0.18	-0.10
Other Income/Expense	1.02	0.00	0.00	-22.85	-0.57
Income
Income Before Tax	-21.66	-15.57	-8.22	-24.38	-1.13
Income Tax Expense	0.04	0.03	0.01	0.01	0.02
Net Income	-21.61	-15.43	-8.23	-24.38	-1.15
Net Income - Continuous Operations	-21.61	-15.60	-8.23	-24.38	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-22.64	-16.14	-8.22	-24.20	-0.45
EBIT	-22.67	-16.14	-8.22	-24.20	-0.45
Depreciation & Amortization	0.03	0.01	0.00	0.00	0.00
Earnings Per Share
Basic EPS	-1.00	-1.00	-1.00	-7.00	-
Diluted EPS	-1.00	-1.00	-1.00	-7.00	-
Basic Shares Outstanding	28.29	17.34	13.89	3.67	3.38
Diluted Shares Outstanding	28.29	17.34	13.89	3.67	3.38